NEW YORK, Mar. 13, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on CVRS, MDXG, MYO, and RWLK which can be accessed for free by signing up to www.wallstequities.com/registration. On Monday, March 12, 2018, the NASDAQ Composite ended the trading
Corindus Vascular Robotics
Waltham, Massachusetts headquartered Corindus Vascular Robotics Inc.'s stock finished Monday's session 6.25% higher at $1.36 with a total trading volume of 1.27 million shares, which is above its three months average volume of 690.62 thousand shares. The Company's shares have advanced 44.67% in the last month, 16.24% in the previous three months, and 25.93% over the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 28.23% and 1.86%, respectively. Additionally, shares of the Company, which designs, manufactures, and sells robotic-assisted precision vascular intervention systems for use in interventional vascular procedures, have a Relative Strength Index (RSI) of 69.97. Get the full research report on CVRS for free by clicking below at: www.wallstequities.com/registration/?symbol=CVRS
On Monday, shares in Marietta, Georgia headquartered MiMedx Group Inc. recorded a trading volume of 2.61 million shares. The stock ended the session 2.16% higher at $7.58. The stock is trading below its 50-day moving average by 41.54%. Moreover, shares of MiMedx, which develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare, have an RSI of 29.96.
On February 26th, 2018, research firm Lake Street downgraded the Company's stock rating from 'Buy' to 'Hold'. Get access to our top-rated research, including the free report on MDXG at: www.wallstequities.com/registration/?symbol=MDXG
Cambridge, Massachusetts headquartered Myomo Inc.'s shares closed the day 0.48% higher at $4.22. The stock recorded a trading volume of 539,018 shares. The Company's shares have gained 32.70% over the previous three months. The stock is trading above its 50-day moving average by 1.94%. Additionally, shares of Myomo, which provides expanded mobility solutions for patients suffering from neurological disorders and upper limb paralysis in the US, have an RSI of 48.90. Click here to subscribe for a free membership which welcomes you with our report on MYO at: www.wallstequities.com/registration/?symbol=MYO
Shares in Yokneam Ilit, Israel headquartered ReWalk Robotics Ltd finished 6.38% higher at $1.25. The stock recorded a trading volume of 332,891 shares, which is above its three months average volume of 286.84 thousand shares. The Company's shares have advanced 19.05% in the last month and 13.64% in the previous three months. The stock is trading above its 50-day moving average by 12.25%. Furthermore, shares of ReWalk Robotics, which designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions, have an RSI of 62.98. Join our big investor community at Wall St. Equities today and get your free report on RWLK at: www.wallstequities.com/registration/?symbol=RWLK
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/stock-review-for-medical-equipments-investors----corindus-vascular-robotics-mimedx-myomo-and-rewalk-robotics-300612943.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Encephalocele is a birth defect where a sac like protrusion of brain and covering membranes occurs ...
Bronchopulmonary dysplasia or chronic lung disease of infancy is seen in premature and low birth ...
Ear, nose and throat are important organs and disease in one area can affect the others. ENT ...View All